Progyny, Inc. (NASDAQ:PGNY – Get Rating) – Investment analysts at Jefferies Financial Group increased their FY2023 earnings estimates for Progyny in a report issued on Monday, May 9th. Jefferies Financial Group analyst G. Santangelo now expects that the company will earn $0.77 per share for the year, up from their prior estimate of $0.75.
A number of other equities research analysts have also recently commented on PGNY. TheStreet cut shares of Progyny from a “c-” rating to a “d+” rating in a report on Friday, January 28th. Zacks Investment Research upgraded shares of Progyny from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Thursday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $65.86.
Shares of NASDAQ PGNY opened at $33.06 on Thursday. The company has a 50 day simple moving average of $43.91 and a two-hundred day simple moving average of $46.82. Progyny has a fifty-two week low of $32.06 and a fifty-two week high of $68.32. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 59.04, a P/E/G ratio of 12.42 and a beta of 2.01.
Progyny (NASDAQ:PGNY – Get Rating) last announced its earnings results on Monday, February 28th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.11. Progyny had a net margin of 10.09{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a return on equity of 24.50{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The business had revenue of $127.55 million during the quarter, compared to the consensus estimate of $134.87 million. During the same quarter last year, the firm earned $0.07 earnings per share. The business’s revenue for the quarter was up 27.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} on a year-over-year basis.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. raised its position in Progyny by 1,469.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. First Horizon Advisors Inc. now owns 769 shares of the company’s stock worth $38,000 after acquiring an additional 720 shares during the period. Fifth Third Bancorp raised its position in Progyny by 1,532.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. Fifth Third Bancorp now owns 1,208 shares of the company’s stock worth $61,000 after acquiring an additional 1,134 shares during the period. Steward Partners Investment Advisory LLC raised its position in Progyny by 44.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,209 shares of the company’s stock worth $61,000 after acquiring an additional 374 shares during the period. Exane Derivatives bought a new position in Progyny in the first quarter worth approximately $69,000. Finally, Captrust Financial Advisors raised its position in Progyny by 19.1{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. Captrust Financial Advisors now owns 1,566 shares of the company’s stock worth $88,000 after acquiring an additional 251 shares during the period. Institutional investors and hedge funds own 82.51{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.
In related news, CEO Peter Anevski sold 600 shares of the firm’s stock in a transaction that occurred on Friday, February 11th. The shares were sold at an average price of $42.00, for a total value of $25,200.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 11th. The stock was sold at an average price of $42.00, for a total transaction of $42,000.00. The disclosure for this sale can be found here. Insiders sold 535,366 shares of company stock worth $22,823,122 in the last 90 days. 14.00{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is currently owned by corporate insiders.
About Progyny (Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
Receive News & Ratings for Progyny Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Progyny and related companies with MarketBeat.com’s FREE daily email newsletter.
